285,000 square foot campus will provide best-in-class work environment and state-of-the-art facilities for the company’s expanding research and development operations
HAYWARD, Calif.–Eikon Therapeutics Inc., a California-based biotechnology company that applies advanced engineering and high-performance computing to the identification of important new medicines, today announced the execution of a long-term lease with Alexandria Real Estate Equities, Inc. for its new corporate headquarters. Eikon’s new headquarters will consist of approximately 285,000 square feet of office and laboratory space on a new life sciences campus being developed by Alexandria in Millbrae, California.
“Eikon Therapeutics was born out of the San Francisco Bay Area’s interconnected community of world-class research universities, venture capital firms, and technology and life sciences companies, and we are proud to expand our presence in the region,” said Roger M. Perlmutter, CEO and Chairman of Eikon Therapeutics. “For nearly three decades, Alexandria has been developing facilities at the vanguard of design for discovery and innovation. We look forward to working with Alexandria to create an inspiring space where our multi-disciplinary teams can even more effectively pursue our mission of delivering therapies that will improve and extend life.”
“Eikon is in an exciting phase of growth that has benefited tremendously from the diverse pool of talent across research, engineering, and technology that exists in the Bay Area. The city of Millbrae has been an important champion of this project, and we are committed to partnering with them to create new opportunities for top local talent seeking high-quality STEM-based careers,” said Alfred “Freddie” Bowie, CFO at Eikon Therapeutics.
Upon completion, the Alexandria Center for Life Science – Millbrae campus will be made up of four structures that together include approximately 637,000 square feet of laboratory and office space, as well as an approximately 16,000 square foot amenity center. The new campus is conveniently situated between Highway 101 and El Camino Real and is across from the Millbrae Transit Center, serviced by both BART and Caltrain. Construction has begun on the site and is expected to be completed in late 2024.
With approximately 285,000 square feet, Eikon Therapeutics will be the anchor tenant of the campus, with space to accommodate up to 750 employees. The environmentally sustainable facility, which is targeting LEED Gold certification, will be custom-built for leading-edge research and will integrate scientific and non-scientific spaces to foster cross-disciplinary collaboration.
“We are proud and honored to welcome Eikon as our world-class anchor tenant at our new Alexandria Center for Life Science – Millbrae campus in the heart of our South San Francisco life science cluster,” said Terezia Nemeth, Executive Vice President – Regional Market Director of the San Francisco Bay Area region for Alexandria Real Estate Equities, Inc. “Our proven track record of delivering high-quality projects on time and on budget, and our stellar reputation for the operational excellence of our complex mission-critical laboratory infrastructure, together with our position as a key leader and collaborator in the life science ecosystem, continue to make us the brand of choice to some the most innovative life science companies in the world, like Eikon. This new campus with robust public transit access as well as uniquely inspiring design and amenities will enable Eikon to recruit the best talent to build its scientific platform to address some of the most challenging diseases known to humankind.”
“Eikon Therapeutics captures the best of the Bay Area’s culture of mission-driven innovation, and we are proud that they have chosen to make Millbrae home to their new headquarters. It is an exciting time of future-looking development in our city, and we look forward to welcoming the entire Eikon team to our community,” said Tom Williams, Millbrae City Manager.
Eikon Therapeutics was represented in this transaction by Cushman & Wakefield.
About Eikon Therapeutics
Eikon Therapeutics is a drug discovery and development company. Our proprietary platform leverages Nobel Prize-winning super-resolution microscopy, advanced engineering, and high-performance computing with the goal of bringing important new medicines to patients suffering from grievous illness. Scientists at Eikon measure the real-time movement of individual proteins in living cells to develop differentiated therapeutics. Eikon is currently based in Hayward, California and can be found online via our website or on Twitter or LinkedIn.